Sarah Williams was named Vice President, Controller and Principal Accounting Officer of AN2 Therapeutics, Inc. As of November 14, 2026, AN2 Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 29, 2026 to March 20, 2026, naming 1 appointment (Form 8-K, January 29, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like AN2 Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
AN2 Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-29 to 2026-03-20. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as AN2 Therapeutics, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2024-08-08 (layoff filings and notices).
Also on the record for AN2 Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 13, 2026 | Stake report, Schedule 13G/A, by Coastlands Capital LP | 9.99% of the class | 5%+ stakes | Source |
| November 13, 2026 | Stake report, Schedule 13G/A, by Eric Easom | 6.2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Almitas Capital LLC | 4.1% of the class | 5%+ stakes | Source |
| March 25, 2026 | Form D, private offering | $40M sold | Form D page | Source |
| March 16, 2026 | Stake report, Schedule 13G, by Commodore Capital LP | 9.9% of the class | 5%+ stakes | Source |
| March 13, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 6.3% of the class | 5%+ stakes | Source |
| March 13, 2026 | Stake report, Schedule 13G, by Vivo Opportunity Fund Holdings, L.P. | 8% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Almitas Capital LLC | 5.4% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Eric Easom | 7.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Almitas Capital LLC | 5.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs AN2 Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on AN2 Therapeutics, Inc. and the records around it.
AN2 Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Form D filing Mar 2026
- Who owns it
Companies that share a holder
- Almitas Capital LLC also filed stake reports on 8 other companies: MFS HIGH YIELD MUNICIPAL TRUST (Aug 2026), MFS INVESTMENT GRADE MUNICIPAL TRUST (Aug 2026), ABRDN JAPAN EQUITY FUND, INC. (Feb 2026)
- Coastlands Capital LP also filed stake reports on 17 other companies: Camp4 Therapeutics Corp (Nov 2026), Eloxx Pharmaceuticals, Inc. (Nov 2026), Minerva Neurosciences, Inc. (Nov 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
Watch AN2 Therapeutics, Inc.
Get an email when AN2 Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on AN2 Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on AN2 Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on AN2 Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-20 | Reported | not named in the filing | 8-K, 2026-03-20 | ||
| 2026-01-29 | In | Vice President, Controller and Principal Accounting Officer | 8-K, 2026-01-29 |
Who leads AN2 Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Vice President, Controller and Principal Accounting Officer: Sarah Williams, appointed (filed 2026-01-29).
New leaders reset buying decisions — get the Full Report on AN2 Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Vice President, Controller and Principal Accounting Officer at AN2 Therapeutics, Inc., with the record behind each one.
Find candidates like Controller and Principal Accounting Officer at AN2 Therapeutics, Inc.Every change, in the filing's words
Reported
The Company's named executive officers hold the following aggregate number of Eligible Options: Eric Easom, President, Chief Executive Officer and Board chair: 742,649 Eligible Options, with original exercise prices ranging from $6.60 - $17.28 per share; Joshua Eizen, Chief Legal Officer and Chief Operating Officer: 142,150 Eligible Options, with original exercise prices ranging from $14.29 - $17.88 per share; and Lucy Day, Chief Financial Officer: 221,965 Eligible Options, with original exercise prices ranging from $6.60 - $17.28 per share.
- Pursuant to the Option Repricing, the exercise price of each Eligible Option was reduced to $3.91 per share, the closing price of the Company's common stock on the Repricing Date.
- To the extent an Eligible Option is exercised prior to the Premium End Date (as defined below), or the eligible holder's services with the Company terminates prior to the Premium End Date, the holder will be required to pay the original exercise price per share of the Eligible Options.
- The "Premium End Date" means the earliest of (i) September 19, 2027, (ii) the date of a change in control, or (iii) the eligible holder's death or disability.
- Except for the reduction in the exercise prices of the Eligible Options as described above, the Eligible Options will retain their existing terms and conditions as set forth in the Plans and the applicable award agreements.
- The Board believes that the Option Repricing with the Premium End Date is in the best interests of the Company, as the amended stock options will provide added incentives to retain and motivate Plan participants without incurring the stock dilution resulting from significant additional equity grants to the eligible participants or significant additional cash expenditures resulting from additional cash compensation.
Appointed: Sarah Williams, Vice President, Controller and Principal Accounting Officer
On January 26, 2026, the Board of Directors (the "Board") of AN2 Therapeutics, Inc. (the "Company") appointed Sarah Williams as Vice President, Controller and Principal Accounting Officer of the Company.
- Ms. Williams assumes the role (effective as of February 1, 2026) from Lucy Day, who will continue as the Company's Chief Financial Officer and its Principal Financial Officer.
- Ms. Williams, age 38, has served as the Company's Corporate Controller since May 2024.
- Prior to joining the Company, Ms. Williams held positions of increasing responsibility at Gritstone Bio, a biotechnology company, from August 2018 to May 2024, including most recently as Controller.
- From August 2016 to August 2018, Ms. Williams served in accounting roles at Bio-Rad Laboratories, a biotech company.
- Previously, Ms. Williams was Assurance Manager at BDO USA, LLP, an accounting firm, from November 2012 to March 2016 and a Senior Associate, Assurance Services at Crowe Horwath LLP, an accounting and consulting firm, from August 2010 to November 2012.
- Ms. Williams holds a Bachelor of Science in Business with a concentration in Accounting from Sonoma State University and is a Certified Public Accountant (inactive).
- In connection with her appointment, Ms. Williams will receive an annual base salary increase to $310,000, with a target annual bonus of 30% of her base salary.
Tools for this story
Each opens in a new tab, filled in for AN2 Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
